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Concomitant Use of Single Antiplatelet Therapy With Edoxaban or
Warfarin in Patients With Atrial Fibrillation: Analysis From the
ENGAGE AF-TIMI48 Trial
Haiyan Xu, MD; Christian T. Ruff, MD, MPH; Robert P. Giugliano, MD, SM; Sabina A. Murphy, MPH; Francesco Nordio, PhD;
Indravadan Patel, MD; Minggao Shi, PhD; Michele Mercuri, MD, PhD; Elliott M. Antman, MD; Eugene Braunwald, MD
Background-—We studied the concomitant use of single antiplatelet therapy (SAPT) on the efﬁcacy and safety of the anti-Xa agent
edoxaban in patients with atrial ﬁbrillation (AF).
Methods and Results-—ENGAGE AF-TIMI 48 was a randomized trial that compared 2 dose regimens of edoxaban with warfarin. We
studied both the approved high-dose edoxaban regimen (HDER; 60 mg daily reduced by one half in patients with anticipated
increased drug exposure), as well as a lower-dose edoxaban regimen (LDER; 30 mg daily, also reduced by one half in patients with
anticipated increased drug regimen). SAPT (aspirin in 92.5%) was administered at the discretion of the treating physician. Cox
proportional hazard regressions stratiﬁed by SAPT at 3 months with treatment as a covariate were performed. The 4912 patients
who received SAPT were more frequently male, with histories of coronary artery disease and diabetes, and had higher CHADS2Vasc
and HAS BLED scores than did the 14 977 patients not receiving SAPT. When compared to patients not receiving SAPT, those
receiving SAPT had a higher incidence of major bleeding; (adjusted hazard ratio [HRadj]=1.46; 95% CI, 1.27–1.67, P<0.001). SAPT
did not alter the relative efﬁcacy of edoxaban compared to warfarin in preventing stroke or systemic embolic events (SEEs):
edoxaban versus warfarin without SAPT, hazard ratio (HRadj for HDER)=0.94; (95% CI: 0.77–1.15) with SAPT, HRadj=0.70 (95% CI:
0.50–0.98), P interaction (Pint)=0.14. (HRadj for LDER versus warfarin without SAPT=1.19 (95% CI 0.99–1.43) With SAPT, 1.03 (95%
CI, 0.76–1.39) Pint=0.42. Major bleeding was lower with edoxaban than warfarin both without SAPT, HRadj for HDER=0.80 (95% CI,
0.68–0.95), and with SAPT, HRadj=0.82 (95% CI, 0.65–1.03; Pint=0.91). For LDER without SAPT (HRadj=0.56 [95% CI 0.46–0.67])
and with SAPT (HRadj=0.51 [95% CI 0.39–0.66]).
Conclusions-—Patients with AF who were selected by their physicians to receive SAPT in addition to an anticoagulant had a similar
risk of stroke/SEE and higher rates of bleeding than those not receiving SAPT. Edoxaban exhibited similar relative efﬁcacy and
reduced bleeding compared to warfarin, with or without concomitant SAPT.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov/. Unique identiﬁer: NCT00781391. ( J Am Heart Assoc. 2016;5:
e002587 doi: 10.1161/JAHA.115.002587)
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A s previously reported, in patients with nonvalvular atrialﬁbrillation (AF), the Effective aNticoaGulation with factor
xA next GEneration in AF-Thrombolysis In Myocardial Infarc-
tion 48 (ENGAGE AF-TIMI 48) trial showed that the factor Xa
inhibitor, edoxaban, was noninferior to warfarin in the
prevention of stroke or systemic embolic event (stroke/SEE)
and resulted in signiﬁcantly lower rates of bleeding and
cardiovascular death.1 Patients with nonvalvular AF are
frequently elderly and have a high prevalence of chronic
coronary artery disease (CAD).2,3 Though oral anticoagulants
are more effective than antiplatelet agents in preventing
stroke/SEE in patients with AF, it is thought that the latter
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may be more protective in reducing vascular events in
patients with CAD or at high risk of acute coronary events.4,5
The choice of optimal antithrombotic management to prevent
both thromboembolic and acute ischemic events in patients
with AF and coexisting CAD is challenging given that
combination therapy of anticoagulant and antiplatelet agents
is associated with an increased risk of bleeding and its
efﬁcacy is not clear.6–10 Here, we report on the effects of
single antiplatelet therapy (SAPT) on the comparison of
edoxaban with warfarin in patients with non-valvular AF.
Methods and Results
Study Population and Treatments
ENGAGE AF-TIMI 48 was a multinational, double-blind
randomized trial that compared the efﬁcacy and safety of 2
dosing regimens of edoxaban with warfarin.1,11 The trial was
approved by all institutional review committees and subjects
provided informed consent. Edoxaban was provided by the
sponsor, Daiichi Sankyo (Parsippany, NY), who also funded
the trial. Brieﬂy, 21 105 patients with a history of docu-
mented AF and a CHADS2 score ≥2 were enrolled. Key
exclusion criteria were severe renal dysfunction (creatinine
clearance [CrCl] <30 mL/min), a high bleeding risk, receiving
or anticipated to receive dual antiplatelet therapy, or a history
of stroke, acute coronary syndrome, or coronary revascular-
ization within 30 days of randomization. The trial studied 2
dose regimens of edoxaban. The higher dose edoxaban
regimen (HDER) was approved by the US Food and Drug
Administration and the European as well as Japanese
Medicine Agencies. This dose (60 mg/day) was reduced to
30 mg/day if any of the following characteristics, which
would be expected to increase drug exposure, were present at
the time of randomization or occurred during the trial12: CrCl
30 to 50 mL/min; body weight ≤60 kg; or concomitant use of
potent P-glycoprotein inhibitors (verapamil, quinidine, or
dronedarone). The lower-dose regimen (LDER) was 30 mg/
day and reduced to 15 mg/day for the same reasons. SAPT
was administered as directed by the treating physician;
aspirin ≤100 mg daily was strongly encouraged. If a clinical
indication for dual antiplatelet therapy arose after random-
ization, the study drug was temporarily interrupted, but open-
label vitamin K antagonist (VKA) was permitted. Warfarin was
well managed during the trial with median time in the
therapeutic range (mTTR) of 68.4%.1
Patients with events (death, stroke, systemic embolic
event [SEE], or major bleeding) occurring before the 3 months
visit were excluded from the primary analysis because a
sizeable percentage of patients (n=498; 7.46%) discontinued
SAPT after they entered the ENGAGE AF-TIMI 48 trial and
were begun on anticoagulant therapy. Therefore, in our
primary analysis we compared SAPT with no SAPT beginning
3 months after randomization. Patients with or without SAPT
use at randomization were evaluated in a sensitivity analysis.
Endpoints
Endpoints were the same as those prespeciﬁed in the
ENGAGE-TIMI 48 trial.1,11,13 The primary efﬁcacy endpoint
was stroke/SEE and the primary safety endpoint was major
bleeding as per the International Society on Thrombosis and
Hemostasis (ISTH) criteria; the primary net clinical outcome
was a composite of stroke/SEE, all-cause death, or major
bleeding. Cardiovascular death, myocardial infarction (MI),
intracranial hemorrhage (ICH), life -threatenig bleeding, and
major plus clinically relevant nonmajor bleeding were also
analyzed.1 All end points were adjudicated by a blinded
clinical endpoint committee.
Statistical Methods
Baseline characteristics across subgroups were compared
using the chi-square test for categorical variables and the
Wilcoxon rank-sum test for continuous variables. The Cox
proportional hazard method was used to calculate the hazard
ratio (HR) of edoxaban to warfarin. Comparison of outcomes
in patients receiving and not receiving SAPT at 3 months was
performed going forward, after adjustment for the following
baseline characteristics: age, sex, geographic region; weight;
CrCl; smoking; CAD; previous MI; previous coronary revascu-
larization; dyslipidemia; diabetes; peripheral arterial disease;
history of carotid arterial disease; type of AF; VKA na€ıve.
Nonlinearity in continuous covariates was handled by cubic
splines. Statistical analyses were performed in SAS software
(version 9.2; SAS Institute, Inc., Cary, NC). All outcomes
reported were annualized.
Results
At enrollment, 7036 subjects were randomized to warfarin,
7035 to the HDER and 7034 to the LDER, respectively
(Figure 1). At randomization, 6678 of the 21 105 subjects
(31.6%) were receiving SAPT and 7.46% of all subjects
discontinued SAPT before the 3-month visit in both the
warfarin and edoxaban groups. The present analysis was
carried out in 19 909 subjects, 4912 of whom (24.7%) were
and 14 977 (75.3%) who were not receiving a SAPT at the 3-
month visit. After the 3 month visit, the percentage of
patients receiving SAPT remained between 24% and 25%
during the remainder of the trial, and the present analysis is
based on these 4912 patients (Table 1). Of the 4912 patients
on SAPT, 4525 (92.5%) were taking aspirin, (most [92%] of
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whom were taking ≤100 mg/day aspirin). The percentage of
patients receiving aspirin at each time point were also similar
(Table S1). The remainder received another antiplatelet agent,
usually clopidogrel.
Patients receiving SAPT were more frequently male,
smokers, and more likely to have a history of CAD, previous
MI, previous coronary revascularization, dyslipidemia, dia-
betes, and carotid and peripheral arterial disease (Table 2),
previous coronary revascularization, paroxysmal AF, a
CHADS2 score ≥4, a CHA2DS2-Vasc score ≥4, a HAS-BLED
score ≥3, and to have been VKA na€ıve at the time of
randomization. During the trial, the mTTR was lower in
patients randomized to warfarin who were on SAPT (67.7%),
compared to those who were not on SAPT (69.0%; P=0.002).
Outcomes in Patients With and Without SAPT
When the 3 arms (warfarin and the 2 edoxaban arms)
were considered together, event rates for the primary
efﬁcacy endpoint (stroke/SEE) for those who received
SAPT (1.71%/year) were similar to those in the non-SAPT
group (1.56%/year; P=0.26). Adjusted HR (HRadj; SAPT vs
no SAPT) was 1.12 (95% CI, 0.95–1.32; P=0.19). Major
bleeding occurred more frequently in patients who
received SAPT (3.37%/year) than not (1.99%/year;
P<0.001); HRadj=1.46 (95% CI, 1.27–1.67; P<0.001;
Figure 2).
In patients randomized to warfarin, those receiving SAPT
had a numerically higher event rate for the primary endpoint
Warfarin
N= 1645
LDER
N= 1625
HDER
N=1642
Randomized patients, 
n=21105
7035 subjects 
randomized to high-
dose edoxaban regimen
7036 subjects randomized 
to warfarin regimen
On SAPT at 3 
months, N = 4912
Not on SAPT at 3 
months,  N = 14997
7034 Subjects randomized 
to low-dose edoxaban 
regimen
1196 Subjects with 
death/stroke/SEE/major 
bleed prior to 3 months, 
end of follow-up, and
missing APT data are 
excluded
Warfarin
N= 4998
LDER
N=5046
HDER
N=4953
Figure 1. Study consort diagram. APT indicates antiplatelet therapy; HDER, high-dose edoxaban registry;
LDER, low dose edoxaban regimen; SEE, systemic embolic event.
Table 1. Prevalence of SAPT Use at Randomization and 6 Time Points Throughout the Study
Landmark Period Total, n/N (%) Warfarin, n/N (%) Low-Dose Edoxaban, n/N (%) High-Dose Edoxaban, n/N (%)
At baseline 6678/21 105 (31.6) 2253/7036 (32.0) 2179/7034 (31.0) 2246/7035 (31.9)
At 3 months 4912/19 909 (24.7) 1645/6643 (24.8) 1625/6671 (24.4) 1642/6595 (24.9)
At 6 months 4618/19 276 (24.0) 1551/6425 (24.1) 1527/6481 (23.6) 1540/6370 (24.2)
At 12 months 4567/18 794 (24.3) 1541/6250 (24.7) 1524/6301 (24.2) 1502/6243 (24.1)
At 18 months 4574/18 470 (24.8) 1518/6147 (24.7) 1525/6201 (24.6) 1531/6122 (25.0)
At 24 months 4447/18 095 (24.6) 1460/6002 (24.3) 1492/6090 (24.5) 1495/6003 (24.9)
At 30 months 3279/13 225 (24.8) 1089/4392 (24.8) 1127/4439 (25.4) 1063/4394 (24.2)
SAPT indicates single antiplatelet therapy.
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(1.88%/year) compared to those in the non SAPT group
(1.49%/year; P=0.08). In the HDER, the primary endpoint
events were similar in the 2 groups (1.31%/year on SAPT vs
1.42%/year not on SAPT; P=0.61; Figure 3), and for the LDER
they were 1.94 (on SAPT) and 1.78 (not on SAPT; P=0.49;
Table 3).
In the warfarin arm, cardiovascular death occurred more
frequently in patients receiving SAPT (3.56%/year) than not
Table 2. Baseline Characteristics in Patients With and Without Antiplatelet Therapy at 3 Months (Including Low Edoxaban Group)
Variables Not on SAPT (N=14 997) On SAPT (N=4912) P Value
Demographic
Age, y, median (IQR) 72.0 (64.0–77.0) 72.0 (64.0–78.0) 0.515
Age ≥75 y, n (%) 5907 (39.4) 1973 (40.2) 0.333
Male, n (%) 9039 (60.3) 3346 (68.1) 0.000
Region (%)
North America 2723 (18.2) 1662 (33.8) 0.000
Latin America 1996 (13.3) 496 (10.1)
Western Europe 2485 (16.6) 508 (10.3)
Eastern Europe 5634 (37.6) 1227 (25.0)
Asia 2159 (14.4) 1019 (20.7)
Clinical factors and medical history
Weight ≤60 kg, n (%) 1408 (9.4) 483 (9.8) 0.356
CrCl at randomization
Median (IQR), mL/min 71.1 (54.5–92.5) 70.0 (53.4–91.9) 0.013
≤50 mL/min, n (%) 2775 (18.5) 966 (19.7) 0.070
Current/former smoker, n (%) 5866 (39.1) 2287 (46.6) 0.000
Previous CAD, n (%) 4172 (27.8) 2403 (48.9) 0.000
Previous MI, n (%) 1395 (9.3) 869 (17.7) 0.000
Previous coronary revascularization, n (%) 1177 (7.8) 1274 (25.9) 0.000
Hypertension, n (%) 14 040 (93.6) 4606 (93.8) 0.705
Dyslipidemia, n (%) 7520 (50.1) 2979 (60.6) 0.000
Diabetes, n (%) 5190 (34.6) 1993 (40.6) 0.000
History of congestive heart failure, n (%) 8669 (57.8) 2762 (56.2) 0.053
Peripheral arterial disease, n (%) 511 (3.4) 278 (5.7) 0.000
Carotid arterial disease, n (%) 744 (5.0) 454 (9.2) 0.000
Previous stroke or TIA, n (%) 4216 (28.1) 1387 (28.2) 0.866
Type of AF
Paroxysmal, n (%) 3530 (23.5) 1510 (30.8) 0.000
Persistent, n (%) 3376 (22.5) 1211 (24.7)
Permanent, n (%) 8089 (53.9) 2189 (44.6)
CHADS2 score ≥4, n (%) 3243 (21.6) 1190 (24.2) 0.000
CHA2DS2-Vasc score ≥4, n (%) 10 301 (68.7) 3694 (75.2) 0.000
HAS-BLED score ≥3, n (%) 5253 (35.0) 3895 (79.3) 0.000
Medication
VKA na€ıve, n (%) 5633 (37.6) 2459 (50.1) 0.000
Dose reduced at randomization, n (%) 3669 (24.5) 1265 (25.8) 0.070
AF indicates atrial ﬁbrillation; CAD, coronary artery disease; CrCl, creatinine clearance; IQR, interquartile range; MI, myocardial infarction; TIA, transient ischemic attack; VKA, vitamin K
antagonist.
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receiving it (2.61%/year; P=0.001). In HDER, corresponding
values were 2.94%/year versus 2.12%/year (P=0.002),
respectively (Figure 3), whereas in LDER these values were
2.69% and 2.34% (P=0.19; Table 3).
In the warfarin arm the primary safety endpoint (ISTH
major bleeding) occurred more frequently in patients receiving
SAPT (4.38%/year) than not (2.54%/year; P<0.001). This was
also the case for patients in the HDER (3.55% and 2.04%;
P<0.001; Figure 4,) as well as in the LDER (2.23% and 1.41%,
respectively; P=0.001; Table 4).
Efﬁcacy of Edoxaban Versus Warfarin Stratiﬁed
by SAPT
HRsadj values for the primary endpoint (stroke/SEE) for HDER
versus warfarin were 0.70 (95% CI, 0.50–0.98) in the SAPT group
and 0.94 (95% CI, 0.77–1.15) in the non-SAPT group (Pint=0.14;
Figure 3). Corresponding HRsadj values for the LDER versus
warfarin comparisons were 1.03 (95% CI, 0.76–1.39) on SAPT
and 1.19 (95% CI, 0.99–1.43) for not on SAPT, respectively (Pint=
0.42). Similar ﬁndings were noted for ischemic stroke (Table 3).
HRsadj values for HDER versus warfarin for cardiovascular
death were similar for those in the SAPT group (HR=0.83; 95%
CI, 0.66–1.05) and in the non-SAPT group (HRadj=0.81; 95% CI,
0.69–0.94; Pint=0.83; Figure 3). The corresponding compar-
isons of HRsadj in LDER versus warfarin were 0.75 (95% CI,
0.59–0.95) and 0.89 (95% CI, 0.77–1.04; Pint=0.21.) (Table 3).
HRsadj values for safety of edoxaban versus warfarin
stratiﬁed by SAPT for the primary safety endpoint (ISTH major
bleeding) were 0.82 (95% CI, 0.65–1.03) in the SAPT group
and 0.80 (95% CI, 0.68–0.95) in the non-SAPT group
(Pint=0.91), whereas corresponding HRsadj value for the LDER
versus warfarin were 0.51 (95% CI, 0.39–0.66) and 0.56 (95%
CI, 0.46–0.67; Pint=0.59). There were consistent reductions in
bleeding (including ICH, life-threatening bleeding, and fatal
Annualized Event Rate (%/yr)
Events No 
SAPT SAPT Adj HR (95% CI)
Stroke/SEE 1.56 1.71 1.12 (0.95, 1.32)
Major bleeding 1.99 3.37 1.46 (1.27, 1.67)
0              .5               1              1.5              2
Figure 2. Outcomes in patients with and without antiplatelet
therapy. Adj HR indicates adjusted hazard ratio; HR, hazard
ratio; SAPT, single antiplatelet therapy; SEE, systemic embolic
event.
Stroke/SEE
No antiplatelet 1.42 1.49 0.94(0.77-1.15)
Antiplatelet 1.31 1.88 0.70(0.50-0.98)
Ischemic stroke
No antiplatelet 1.20 1.07 1.11(0.89-1.39)
Antiplatelet 0.86 1.19 0.73(0.48-1.11)
Hemorrhagic stroke
No antiplatelet 0.16 0.36 0.45(0.27-0.74)
Antiplatelet 0.40 0.61 0.66(0.36-1.20)
Myocardial infarction
No antiplatelet 0.53 0.59 0.89(0.65-1.22)
Antiplatelet 0.79 0.94 0.85(0.54-1.34)
CV death
No antiplatelet 2.12 2.61 0.81(0.69-0.94)
Antiplatelet 2.94 3.56 0.83(0.66-1.05)
0.1               1              10
Annualized Event Rate (%/yr)
Efficacy          Edox Warf                                            HR (95%CI)            Pint
0.14
0.08
0.33
0.87
0.83
← Edox better        Warf better →
Figure 3. Efﬁcacy endpoints of high dose edoxaban strategy vs warfarin in patients with and without
antiplatelet therapy. CV death indicates cardiovascular death; Edox, edoxaban; HR, hazard ratio; SEE,
systemic embolic event; Warf, warfarin.
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bleeding) with both edoxaban regimens compared to warfarin,
with and without concomitant SAPT (Figure 4; Table 4).
The prespeciﬁed net clinical outcome, which consisted of
both efﬁcacy and safety endpoints, occurred signiﬁcantly
more frequently in patients in the SAPT group, in all 3 arms
(warfarin and both edoxaban arms; Figure 4; Table 4). HRsadj
value of HDER to warfarin were similar in the 2 groups as well,
with HRsadj of 0.82 (95% CI, 0.71–0.95) and 0.89 (95% CI,
0.81–0.98) in the SAPT and non-SAPT groups, respectively
(Pint=0.35; Figure 4). Corresponding values for HRsadj of LDER
to warfarin were 0.72 (95% CI: 0.62–0.84) and 0.89 (95% CI,
0.81–0.98; Pint=0.02; Table 4).
Sensitivity Analyses Stratiﬁed by SAPT at
Randomization
The results of the sensitivity analysis for the comparison of
outcomes of the edoxaban regimen compared to warfarin
stratiﬁed by SAPT at randomization yielded similar results to
those in the principal analysis, described above.
Findings With Aspirin
The results presented in Figures 3 and 4 and in Tables S2 and
S3 for all patients receiving SAPT, were quite similar for the
Table 3. Efﬁcacy Endpoints of Low Dose Edoxaban Strategy
Outcome
Annualized
Event Rate
(%/year) LDE vs WAR
LDE WAR HR (95% CI) Pint
Stroke/SEE
No antiplatelet 1.78 1.49 1.19 (0.99–1.43)
Antiplatelet 1.94 1.88 1.03 (0.76–1.39) 0.42
Ischemic stroke
No antiplatelet 1.55 1.07 1.44 (1.17–1.78)
Antiplatelet 1.64 1.19 1.37 (0.96–1.96) 0.83
Hemorrhagic stroke
No antiplatelet 0.14 0.36 0.38 (0.22–0.65)
Antiplatelet 0.18 0.61 0.29 (0.13–0.64) 0.59
Myocardial infarction
No antiplatelet 0.76 0.59 1.29 (0.97–1.72)
Antiplatelet 0.89 0.94 0.95 (0.61–1.47) 0.24
Cardiovascular death
No antiplatelet 2.34 2.61 0.89 (0.77–1.04)
Antiplatelet 2.69 3.56 0.75 (0.59–0.95) 0.21
HR indicates adjusted hazard ratio; LDE, low dose edoxaban strategy; SEE, systemic
embolic event; WAR, warfarin.
Major bleeding
No antiplatelet 2.04 2.54 0.80(0.68-0.95)
Antiplatelet 3.55 4.38 0.82(0.65-1.04)
Fatal bleeding
No antiplatelet 0.17 0.24 0.70(0.39-1.23)
Antiplatelet 0.19 0.56 0.34(0.15-0.81)
Intracranial bleeding
No antiplatelet 0.27 0.57 0.47(0.31-0.71)
Antiplatelet 0.54 1.18 0.46(0.27-0.79)
Life-threatening bleeding
No antiplatelet 0.36 0.64 0.56(0.39-0.79)
Antiplatelet 0.63 1.14 0.56(0.35-0.88)
Any bleeding
No antiplatelet 9.72 11.07 0.88(0.80-0.95)
Antiplatelet 14.93 18.66 0.80(0.71-0.91)
Net: Death/Stroke/SEE/Major bleeding
No antiplatelet 5.84 6.50 0.89(0.81-0.98)
Antiplatelet 7.75 9.47 0.82(0.71-0.95)
0.1               1              10
Annualized Event Rate (%/yr)
Efficacy          Edox Warf                                            HR (95%CI)            Pint
0.91
0.17
0.98
1.00
0.25
0.35
← Edox better        Warf better →
Figure 4. Bleeding endpoints and net clinical outcome of high dose edoxaban strategy vs warfarin in
patients with and without antiplatelet therapy. Edox indicates edoxaban; HR, hazard ratio; SEE, systemic
embolic event; Warf, warfarin.
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large subgroup (92.5%) of SAPT patients receiving aspirin
(Tables S2 and S3).
Discussion
Current guidelines recommend that low-dose aspirin (75–
100 mg/day) and/or a P2Y12 antagonist may be given
concurrently with an anticoagulant to prevent myocardial
ischemic events and stroke in AF patients after coronary
revascularization, a recent acute coronary syndrome or with
high-risk CAD. The associated increased risk of bleeding
should be evaluated and efforts made to minimize it whenever
possible.10,14–18 Also, the American Heart Association/Amer-
ican College of Cardiology Foundation guideline for secondary
prevention in patients with AF and coronary or other
atherosclerotic vascular disease recommends treatment with
warfarin and low-dose aspirin (≤100 mg daily).14 However, for
AF patients with stable coronary or peripheral arterial disease
(ie, no acute events or revascularization for ≥12 months), oral
anticoagulant therapy without antiplatelet therapy may be
considered.10,16 In clinical practice, a combination of antico-
agulant and dual antiplatelet therapy (triple antithrombotic
therapy) may be administered, preferably for short periods in
patients with AF who are at very high risk of a platelet-driven
event, such as patients with a recent acute coronary
syndrome or stent implantation.19 This increases the risk of
serious bleeding and it should be reduced to double therapy
(ie, an anticoagulant together with SAPT) whenever, or as
soon as, possible.
The present report from the ENGAGE AF-TIMI 48 trial
provides data on the relative efﬁcacy and safety of combina-
tion antithrombotic therapy. At the time of enrollment,
approximately one-third of patients were receiving SAPT,
usually aspirin. SAPT was discontinued in one quarter of these
patients after randomization to anticoagulant therapy. SAPT
was prescribed by the treating physician more commonly in
patients with established CAD, diabetes, dyslipidemia, periph-
eral arterial disease, and those who were therefore at higher
risk of development of acute coronary syndromes than were
patients without these comorbidities. SAPT administration
was used most frequently in North America and less
frequently elsewhere. This difference may be explained, at
least in part, by the greater frequency of patients at high risk
enrolled in North America.
We observed that the addition of SAPT to an anticoagulant
(warfarin or edoxaban) was associated with a signiﬁcantly
greater risk of bleeding. However, the addition of SAPT did not
modify the relative efﬁcacy and safety of edoxaban as
compared to warfarin. Notably, when compared to warfarin,
both edoxaban regimens signiﬁcantly reduced all forms of
bleeding, including ICH and life-threatening bleeding, both in
patients who were as well as those who were not, receiving a
SAPT.
The trade-off between beneﬁt and safety of adding SAPT to
an anticoagulant in patients with both AF and CAD or others
at risk of an acute coronary event is often challenging for
clinicians.9,10 A meta-analysis of 10 randomized trials com-
paring the combination of an oral anticoagulant and aspirin
with anticoagulant alone in patients with AF at risk of
coronary events showed no reduction in arterial thromboem-
bolic events in favor of the combination, but did show an
increased risk of major bleeding.20 Lamberts et al. examined
the efﬁcacy and safety of adding aspirin to a VKA in AF
patients with stable CAD in a nation-wide Danish registry.8
Like the meta-analysis, they found that the risk of coronary
events with the combination was similar to that observed with
VKA alone, whereas the risk of bleeding increased signiﬁ-
cantly when aspirin or clopidogrel were added to VKA. The
WOEST (What is the Optimal antiplateElet and anticoagulant
therapy in patients with oral anticoagulation and coronary
StenTing) trial compared dual therapy (VKA plus clopidogrel)
to triple therapy (VKA, clopidogrel and aspirin) in patients
receiving oral anticoagulants undergoing PCI. Dual therapy
was associated with a signiﬁcant reduction in bleeding
without an increase in rate of thrombotic events.21
Table 4. Bleeding Endpoint and Net Clinical Outcome of LDE
Safety
Annualized Event
Rate (%/year) LDE vs WAR
LDE WAR HR (95% CI) Pint
Major bleeding
No antiplatelet 1.41 2.54 0.56 (0.46–0.67)
Antiplatelet 2.23 4.38 0.51 (0.39–0.66) 0.59
Fatal bleeding
No antiplatelet 0.11 0.24 0.47 (0.25–0.9)
Antiplatelet 0.13 0.56 0.23 (0.09–0.61) 0.22
Intracranial bleeding
No antiplatelet 0.23 0.57 0.40 (0.26–0.62)
Antiplatelet 0.21 1.18 0.18 (0.08–0.37) 0.07
Life-threatening
No antiplatelet 0.34 0.64 0.52 (0.37–0.74)
Antiplatelet 0.31 1.14 0.28 (0.15–0.5) 0.07
Any bleeding
No antiplatelet 7.47 11.07 0.67 (0.62–0.74)
Antiplatelet 13.04 18.66 0.69 (0.61–0.79) 0.73
Net: death/stroke/SEE/major bleeding
No antiplatelet 5.81 6.50 0.89 (0.81–0.98)
Antiplatelet 6.91 9.47 0.72 (0.62–0.84) 0.02
HR indicates adjusted hazard ratio; LDE, low dose edoxaban strategy; SEE, systemic
embolic event; WAR, warfarin.
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Our results with edoxaban are generally consistent with
earlier studies. The Apixaban for Reduction in Stroke and
Other Thromboembolic Events in Atrial Fibrillation (ARISTO-
TLE,) 22 and the Rivaroxaban Once-daily, oral, direct Factor Xa
inhibition Compared with vitamin K antagonism for prevention
of stroke and Embolism Trial in Atrial Fibrillation (ROCKET
AF)23 trials showed that concomitant aspirin use did not alter
the relative effects of apixaban and rivaroxaban on stroke/
SEE and major bleeding compared to warfarin. In the
Randomized Evaluation of Long-term Anticoagulation Therapy
(RE-LY) trial, the addition of SAPT did not affect the safety and
relative efﬁcacy of dabigatran 110 mg BID when compared to
warfarin. However, in contrast to our ﬁndings, the effect of
dabigatran 150 mg BID on the reduction of stroke/SEE
appeared to be attenuated among patients receiving an
antiplatelet agent (HR, 0.80) in comparison to those who were
not (HR=0.52, Pint=0.058).
24
Limitations
Patients with recent acute coronary syndrome, or recent stent
implantation were excluded from this trial. Therefore, the
results may be applicable only to patients in whom a single
antiplatelet agent may be indicated. One of the limitations of
this analysis is that it was based on SAPT at 3 months rather
than at randomization, because a sizeable percentage of
patients (25%) discontinued SAPT after they entered the
ENGAGE AF trial. Therefore, the events occurring during the
ﬁrst 3 months post-randomization were not included in the
analysis reported herein. However, the sensitivity analysis
which included all patients who entered the trial exhibited
similar results. Administration of SAPT was not randomized,
and although the analyses were adjusted for the baseline
characteristics, such adjustments are never complete. In the
future, randomized controlled trials on the outcomes of new
oral anticoagulants with and without SAPT would be informa-
tive.
Conclusions
Patients with nonvalvular AF who were prescribed a single
antiplatelet agent along with concomitant anticoagulant
therapy had higher risks of bleeding than those who were
prescribed only an anticoagulant. However, combination
therapy did not alter the reduction in bleeding in both dose
strategies of edoxaban compared with well-managed warfarin.
All forms of bleeding were highest in patients randomized to
warfarin who were treated with a SAPT. Because of this
ﬁnding, patients with AF who are deemed to require the
addition of a SAPT should receive a Xa inhibitor for
anticoagulation whenever possible.
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